Synthetic lethal targeting of ARID1A-Mutant ovarian clear cell tumors with dasatinib

Molecular Cancer Therapeutics

Volumn 15, Issue 7, 2016, Pages 1472-1484

  Miller, Rowan E ^a   Brough, Rachel ^a   Bajrami, Ilirjana ^a   Williamson, Chris T ^a   McDade, Simon ^b   Campbell, James ^a   Kigozi, Asha ^a   Rafiq, Rumana ^a   Pemberton, Helen ^a   Natrajan, Rachel ^a   Joel, Josephine ^c   Astley, Holly ^c   Mahoney, Claire ^c   Moore, Jonathan D ^c   Torrance, Chris ^c   Gordan, John D ^d   Webber, James T ^d   Levin, Rebecca S ^e   Shokat, Kevan M ^e   Bandyopadhyay, Sourav ^d   Lord, Christopher J ^a   Ashworth, Alan ^a   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c Molecular Biotechnology Center   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AT RICH INTERACTIVE DOMAIN CONTAINING PROTEIN 1A; DASATINIB; PROTEIN; PROTEIN P21; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ARID1A PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FUNCTIONAL GENOMICS; G1 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUTANT; NONHUMAN; OVARIAN CLEAR CELL CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DEFICIENCY; S PHASE CELL CYCLE CHECKPOINT; TUMOR CELL; ADENOCARCINOMA, CLEAR CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION PROFILING; GENETICS; LETHAL MUTATION; METABOLISM; MOLECULARLY TARGETED THERAPY; OVARIAN NEOPLASMS; PATHOLOGY; PRECLINICAL STUDY; TUMOR CELL LINE;

ADENOCARCINOMA, CLEAR CELL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DASATINIB; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); RETINOBLASTOMA PROTEIN; SYNTHETIC LETHAL MUTATIONS; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84979211645     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0554     Document Type: Article

References (51)

1. Anglesio MS, Carey MS, Kobel M, Mackay H, Huntsman DG. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol 2011;121:407-15.
2. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008;109:370-6.
3. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2006; 102:285-91.
4. Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, Roden R, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010;330:228-31.
5. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532-43.
6. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1.
7. Katagiri A, Nakayama K, Rahman MT, Rahman M, Katagiri H, Nakayama N, et al. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol 2012;25:282-8.
8. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011;11:481-92.
9. Gao X, Tate P, Hu P, Tjian R, Skarnes WC, Wang Z. ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a. Proc Natl Acad Sci U S A 2008;105:6656-61.
10. Nagl NGJr, Patsialou A, Haines DS, Dallas PB, Beck GRJr, Moran E. The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. Cancer Res 2005;65:9236-44.
11. Weissman B, Knudsen KE. Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Resarch 2009;69: 8223-30.
12. Inoue H, Furukawa T, Giannakopoulos S, Zhou S, King DS, Tanese N. Largest subunits of the human SWI/SNF chromatin-remodeling complex promote transcriptional activation by steroid hormone receptors. J Biol Chem 2002;277:41674-85.
13. Lemon B, Inouye C, King DS, Tjian R. Selectivity of chromatin-remodelling cofactors for ligand-activated transcription. Nature 2001;414:924-8.
14. Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1Amutated cancers. Nat Med 2015;21:231-8.
15. Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov 2015;5:752-67.
16. Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med 2014;20:251-4.
17. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell 2011;145:30-8.
18. Lord CJ, Martin SA, Ashworth A. RNA interference screening demystified. J Clin Pathol 2009;62:195-200.
19. Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakshandehroo T, et al. Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. Cancer Discov 2015;5:154-67.
20. Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, et al. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep 2014;8:1037-48.
21. Choi M, Chang CY, Clough T, Broudy D, Killeen T, MacLean B, et al. MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments. Bioinformatics 2014;30:2524-6.
22. Brough R, Frankum JR, Sims D, Mackay A, Mendes-Pereira AM, Bajrami I, et al. Functional viability profiles of breast cancer. Cancer Discov 2011;1: 260-73.
23. Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, et al. Type-specific cell line models for type-specific ovarian cancer research. PLoS One 2013;8:e72162.
24. Guan B, Wang TL, Shih Ie M. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 2011;71:6718-27.
25. Huang HN, Lin MC, Huang WC, Chiang YC, Kuo KT. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma. Mod Pathol 2014;27:983-90.
26. Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 2012;22:2120-9.
27. Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, et al. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer 2014;14:120.
28. Samartzis EP, Gutsche K, Dedes KJ, Fink D, Stucki M, Imesch P. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget 2014;5:5295-303.
29. Khan IF, Hirata RK, Russell DW. AAV-mediated gene targeting methods for human cells. Nat Protoc 2011;6:482-501.
30. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, et al. Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol 2010;17:1241-9.
31. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007;25:1035-44.
32. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32.
33. Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, Nishiwaki E, et al. Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells 2013;18:110-22.
34. Guerrouahen BS, Futami M, Vaklavas C, Kanerva J, Whichard ZL, Nwawka K, et al. Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res 2010;16:1149-58.
35. Inge LJ, Fowler AJ, Paquette KM, Richer AL, Tran N, Bremner RM. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia. J Thorac Cardiovasc Surg 2013;145:531-8.
36. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005;11:6924-32.
37. Michels S, Trautmann M, Sievers E, Kindler D, Huss S, Renner M, et al. SRC signaling is crucial in the growth of synovial sarcoma cells. Cancer Res 2013;73:2518-28.
38. Song Y, Sun X, Bai WL, Ji WY. Antitumor effects of Dasatinib on laryngeal squamous cell carcinoma in vivo and in vitro. Eur Arch Otorhinolaryngol 2013;270:1397-404.
39. Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, et al. The role of p27 (Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. J Natl Cancer Inst 2011;103:1403-22.
40. Le XF, Mao W, Lu Z, Carter BZ, Bast RCJr. Dasatinib induces autophagic cell death in human ovarian cancer. Cancer 2010;116:4980-90.
41. Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006;66:5542-8.
42. Chan D, Tyner JW, Chng WJ, Bi C, Okamoto R, Said J, et al. Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo. Oncol Lett 2012;3:807-15.
43. Garcia-Gomez A, Ocio EM, Crusoe E, Santamaria C, Hernandez-Campo P, Blanco JF, et al. Dasatinib as a bone-modifying agent: anabolic and antiresorptive effects. PLoS One 2012;7:e34914.
44. Nagathihalli NS, Merchant NB. Src-mediated regulation of E-cadherin and EMT in pancreatic cancer. Front Biosci 2012;17:2059-69.
45. Flores-Alcantar A, Gonzalez-Sandoval A, Escalante-Alcalde D, Lomeli H. Dynamics of expression of ARID1A and ARID1B subunits in mouse embryos and in cells during the cell cycle. Cell Tissue Res 2011;345: 137-48.
46. Ling C, Chen G, Chen G, Zhang Z, Cao B, Han K, et al. A deuterated analog of dasatinib disrupts cell cycle progression and displays antinon-small cell lung cancer activity in vitro and in vivo. Int J Cancer 2012;131:2411-9.
47. Hochhaus A, Kantarjian H. The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. J Cancer Res Clin Oncol 2013;139:1971-84.
48. Liu-Dumlao T, Kantarjian H, Thomas DA, O'Brien S, Ravandi F. Philadelphia-positive acute lymphoblastic leukemia: current treatment options. Curr Oncol Rep 2012;14:387-94.
49. Puls LN, Eadens M, Messersmith W. Current status of SRC inhibitors in solid tumor malignancies. Oncologist 2011;16:566-78.
50. Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, et al. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012;127:70-4.
51. Secord AA, Teoh DK, Barry WT, Yu M, Broadwater G, Havrilesky LJ, et al. A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. Clin Cancer Res 2012;18:5489-98.